Levee Medical, a Durham, NC-based medical device company focused on improving outcomes for prostate cancer surgery patients, raised $10M in Series B financing.
This raise brought the total amount to $14M. Backers were undisclosed.
The company intends to use the funds to accelerate the development of the Voro Urologic Scaffold.
Led by CEO Adam Irving, Levee Medical is committed to designing solutions that aim to reduce complications associated with surgical treatment for prostate cancer. The Voro Urologic Scaffold, the first product Levee plans to bring to market, is an absorbable device designed to reduce post-prostatectomy urinary incontinence and to support ongoing clinical studies, including an upcoming U.S. pivotal trial and current ARID studies.
This device is an investigational device, is not FDA cleared or approved and is currently in the research and development phase and is not available for sale in any country.
FinSMEs
11/02/2025